Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time.
Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations.
No Improvement in Overall Survival Between Patients with KRAS G12C NSCLC and Patients with non-KRAS G12C NSCLC
Patients with KRAS G12C non–small-cell lung cancer appear to have improved progression-free survival before immunotherapy than patients with non-KRAS G12C lung cancer, but there was no improvement in overall survival between the 2 groups.
Rechallenge with Immune Checkpoint Inhibitors in Patients with Lung Cancer Associated with More Severe Interstitial Lung Disease
More severe interstitial lung disease with more severe radiological features was found on second occurrence in patients with lung cancer who were rechallenged with ICI treatment.
Liquid biopsy improves turnaround time for molecular genotyping, but further improvement in next-generation sequencing is recommended.
A recent study identified several risk factors associated with the development of nephrotoxicity when using pemetrexed in patients with non–small-cell lung cancer.
Researchers identified an association between nutritional status, treatment protocols, and survival in patients with advanced non–small-cell lung cancer.
Recently released study findings on PD-1/PD-L1 immunotherapy in young and elderly patients with metastatic NSCLC found the treatment is safe and effective in both patient cohorts.
Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost.
Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer.
Immune Checkpoint Inhibitors May Have Limited Efficacy in Patients with NSCLC with Poor Performance Status
A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status.
Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications.
Current Selective KRAS G12C Therapies in Non–Small-Cell Lung Cancer and Future Direction for Research
The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article.
Assessing Factors Predictive of Pneumonitis Development with Use of Targeted Therapies in Non–Small-Cell Lung Cancer
In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer.
Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article.
Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result.
A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs.
Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors.
A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin.
A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect.
Evaluation of KRAS G12C Mutation in Non–Small-Cell Lung Cancer Demonstrates Genetic Profile Differences Between Initial Diagnosis and Progressive Disease
Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease.
Social Listening Investigations Can Provide Insights into Patients’ Perception of Lung Cancer Treatment
Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research.
Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials.
The Role of Self-Care Behaviors in Patients on Oral Anticancer Agents in Maximizing Medication Adherence
Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence.
Providing quality care requires understanding the disease factors, clinical presentation, and management strategies for immunotherapy-induced cytokine release syndrome with acute lymphoblastic leukemia treatment.
An overview of the clinical presentation, management approaches, and clinical practice guidelines for immunotherapy-related neurotoxicity in acute lymphoblastic leukemia treatment is presented.
Clinicians should recognize the prognostic importance of minimal residual disease testing and its implications for treatment pathways in acute lymphoblastic leukemia.
Navigating the complexities of acute lymphoblastic leukemia treatment requires a multidisciplinary team approach to the management of multiple care needs in inpatient and outpatient settings.
Successful transitions of care from the hospital to the home setting for patients with acute lymphoblastic leukemia requires a team of hospital and outpatient clinicians to provide coordinated care and support.
Nivolumab Demonstrates Significant Overall Survival Benefits in Patients with Previously Treated Esophageal Squamous-Cell Carcinoma Compared with Chemotherapy
Web Exclusives | December 14, 2021
In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy.
Page 1 of 7
Results 1 - 30 of 198
Results 1 - 30 of 198